Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daptomycin Safety and Efficacy in Renal Impairment (RENSE)
NCT01104662Phase 4Terminated
- Sponsor
- Merck & Co.
- Start
- Apr 2010
- Primary completion
- Jun 2012
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of daptomycin in Skin and Skin Structure Infection (SSSI), Staphylococcus aureus bacteremia (SAB), sponsored by Merck & Co.. Started Apr 2010; status: terminated.
02
Drugs
daptomycin
03
Conditions
Skin and Skin Structure Infection (SSSI)Staphylococcus aureus bacteremia (SAB)
Beyond the preview
Go deeper on NCT01104662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01104662.